Clinical Trial

Seronegative Myasthenia Gravis - Efgartigimod IV

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
This is to study the efficacy, safety and tolerability of efgartigimod in patients with seronegative generalized myasthenia gravis. This is an open label study. There will be 30 participants to enroll at University Health Network Toronto General Hospital. Study duration is 43 weeks from screening to end of study.
Trial Details
NCT Number NCT06587867
Lead Sponsor University Health Network, Toronto
Conditions Efgartigimod, Generalized Myasthenia Gravis
Enrollment 30 participants
Start Date 2023-06-01
Primary Completion 2025-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-09-19